MLH1-deficient HCT116 Colon Tumor Cells Exhibit Resistance to the Cytostatic and Cytotoxic Effect of the Poly(A) Polymerase Inhibitor Cordycepin (3'-deoxyadenosine) in Vitro

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Jun 29

PMID 22740928

Citations 7

Authors

Patrick Imesch

Anouk Goerens

Daniel Fink

Andre Fedier

Affiliations

Soon will be listed here.

Abstract

Cordycepin (3'-deoxyadenosine) is an inhibitor of poly(A) polymerase (PAP), an enzyme crucial to mRNA 3'-end processing, which produces the shortening of poly(A) tails, leading to the destabilization of mRNAs. Cordycepin inhibits proliferation and induces apoptosis in tumor cells, indicating its antitumor activity. Defective 3'-end processing is associated with hypersensitivity to UV treatment. We investigated the effects of cordycepin on proliferation and apoptosis in MLH1-deficient and MLH1-proficient HCT116 colon tumor cells. MLH1 is a DNA mismatch repair (MMR) protein involved in the processing of damaged DNA. Cells with defective MMR show resistance to certain anticancer drugs. The results showed that MLH1-deficient HCT116 cells are 2-fold less sensitive to the cytostatic effect of cordycepin, as compared to MLH1-proficient cells. This reduced sensitivity to cordycepin in MLH1-deficient cells was associated with reduced upregulation of the cell cycle inhibitor p21. MLH1-deficient cells also exhibited reduced susceptibility to apoptosis upon treatment with cordycepin, as demonstrated by the reduced PARP-1 cleavage. Our findings showed that MLH1-deficient HCT116 colon tumor cells are resistant to the cytostatic and cytotoxic effect of cordycepin, indicating a possible involvement of MMR in mRNA polyadenylation. The findings also suggest that cordycepin is not suitable to therapeutically encounter tumor cells lacking MLH1 expression.

Citing Articles

DNA-PKcs suppresses illegitimate chromosome rearrangements.

Wang J, Sadeghi C, Frock R Nucleic Acids Res. 2024; 52(9):5048-5066.

PMID: 38412274 PMC: 11109964. DOI: 10.1093/nar/gkae140.

Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells.

Contursi A, Fullone R, Szklanna-Koszalinska P, Marcone S, Lanuti P, Taus F Cancers (Basel). 2023; 15(2).

PMID: 36672299 PMC: 9856452. DOI: 10.3390/cancers15020350.

Tussah silkmoth pupae improve anti-tumor properties of (L.) Link by increasing the levels of major metabolite cordycepin.

Wen Z, Du X, Meng N, Li Y, Mi R, Li X RSC Adv. 2022; 9(10):5480-5491.

PMID: 35515955 PMC: 9060897. DOI: 10.1039/c8ra09491h.

A Systematic Review of the Biological Effects of Cordycepin.

Radhi M, Ashraf S, Lawrence S, Tranholm A, Wellham P, Hafeez A Molecules. 2021; 26(19).

PMID: 34641429 PMC: 8510467. DOI: 10.3390/molecules26195886.

The Anticancer Properties of Cordycepin and Their Underlying Mechanisms.

Yoon S, Park S, Park Y Int J Mol Sci. 2018; 19(10).

PMID: 30287757 PMC: 6212910. DOI: 10.3390/ijms19103027.

References

Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M . Antitumor effect of cordycepin (3'-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res. 2006; 26(1A):43-7. View

Cevher M, Zhang X, Fernandez S, Kim S, Baquero J, Nilsson P . Nuclear deadenylation/polyadenylation factors regulate 3' processing in response to DNA damage. EMBO J. 2010; 29(10):1674-87. PMC: 2876964. DOI: 10.1038/emboj.2010.59. View

Wong Y, Moon A, Duffin R, Barthet-Barateig A, Meijer H, Clemens M . Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem. 2009; 285(4):2610-21. PMC: 2807318. DOI: 10.1074/jbc.M109.071159. View

Nakamura K, Konoha K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K . Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo. 2005; 19(1):137-41. View

Muller W, Seibert G, Beyer R, Breter H, Maidhof A, Zahn R . Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res. 1977; 37(10):3824-33. View

Nehme A, Baskaran R, Nebel S, Fink D, Howell S, Wang J . Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer. 1999; 79(7-8):1104-10. PMC: 2362240. DOI: 10.1038/sj.bjc.6690176. View

Wu W, Hsiao J, Lian Y, Lin C, Huang B . The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol. 2006; 60(1):103-11. DOI: 10.1007/s00280-006-0354-y. View

Fedier A, Fink D . Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol. 2004; 24(4):1039-47. View

Thomadaki H, Scorilas A, Tsiapalis C, Havredaki M . The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol. 2007; 61(2):251-65. DOI: 10.1007/s00280-007-0467-y. View

10.

Penman S, Rosbash M, Penman M . Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin. Proc Natl Acad Sci U S A. 1970; 67(4):1878-85. PMC: 283442. DOI: 10.1073/pnas.67.4.1878. View

11.

Chen L, Du-Cuny L, Vethantham V, Hawke D, Manley J, Zhang S . Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol. 2009; 79(5):669-77. PMC: 2812641. DOI: 10.1016/j.bcp.2009.09.028. View

12.

Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J . Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res. 2000; 60(19):5427-33. View

13.

Lee S, Moon G, Jung K, Kim W, Moon S . c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem Toxicol. 2009; 48(1):277-83. DOI: 10.1016/j.fct.2009.09.042. View

14.

Chang W, Lim S, Song H, Song B, Kim H, Cha M . Cordycepin inhibits vascular smooth muscle cell proliferation. Eur J Pharmacol. 2008; 597(1-3):64-9. DOI: 10.1016/j.ejphar.2008.08.030. View

15.

Jiricny J . The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006; 7(5):335-46. DOI: 10.1038/nrm1907. View

16.

Mirkin N, Fonseca D, Mohammed S, Cevher M, Manley J, Kleiman F . The 3' processing factor CstF functions in the DNA repair response. Nucleic Acids Res. 2008; 36(6):1792-804. PMC: 2330234. DOI: 10.1093/nar/gkn005. View

17.

Peltomaki P . Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003; 21(6):1174-9. DOI: 10.1200/JCO.2003.04.060. View

18.

Gartel A, Radhakrishnan S . Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005; 65(10):3980-5. DOI: 10.1158/0008-5472.CAN-04-3995. View

19.

Riedl S, Salvesen G . The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007; 8(5):405-13. DOI: 10.1038/nrm2153. View

20.

Nazeer F, Devany E, Mohammed S, Fonseca D, Akukwe B, Taveras C . p53 inhibits mRNA 3' processing through its interaction with the CstF/BARD1 complex. Oncogene. 2011; 30(27):3073-83. DOI: 10.1038/onc.2011.29. View